Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
7.10
-0.40 (-5.33%)
At close: Dec 2, 2025, 4:00 PM EST
6.32
-0.78 (-11.02%)
After-hours: Dec 2, 2025, 6:47 PM EST
Exagen Employees
As of December 31, 2024, Exagen had 215 total employees, including 209 full-time and 6 part-time employees. The number of employees increased by 36 or 20.11% compared to the previous year.
Employees
215
Change (1Y)
36
Growth (1Y)
20.11%
Revenue / Employee
$295,809
Profits / Employee
-$88,553
Market Cap
160.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 215 | 36 | 20.11% |
| Dec 31, 2023 | 179 | -25 | -12.25% |
| Dec 31, 2022 | 204 | -18 | -8.11% |
| Dec 31, 2021 | 222 | 39 | 21.31% |
| Dec 31, 2020 | 183 | 30 | 19.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XGN News
- 21 days ago - Exagen Inc. to Participate in Fourth Quarter Investor Conferences - GlobeNewsWire
- 4 weeks ago - Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Exagen Inc. Reports Strong Q3 2025 Results - GlobeNewsWire
- 5 weeks ago - Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence - GlobeNewsWire
- 6 weeks ago - Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 4 months ago - Exagen Inc. to Participate in Third Quarter Investor Conferences - GlobeNewsWire
- 4 months ago - Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Exagen Q2 Revenue Jumps 14 Percent - The Motley Fool